Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized Phase 2 trial designed to evaluate the efficacy and safety of SRF388 in
combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in
combination with atezolizumab plus bevacizumab in patients with first-line advanced or
metastatic HCC.